Drug interactions between Inderide and Invirase
| Results for the following 2 drugs: |
|---|
| Inderide (hydrochlorothiazide/propranolol) |
| Invirase (saquinavir) |
Interactions between your selected drugs
propranolol ↔ saquinavir
Applies to:Inderide (hydrochlorothiazide/propranolol) and Invirase (saquinavir)
GENERALLY AVOID: Saquinavir in combination with ritonavir has been shown to prolong the PR interval of the electrocardiogram in some patients. Theoretically, coadministration with other agents that prolong the PR interval (e.g., beta blockers, digoxin, diltiazem, lacosamide, mefloquine, verapamil) may result in additive effects and increased risk of bradycardia and heart block. In a study of 59 healthy volunteers aged 18 to 55 years, PR interval prolongation greater than 200 msec (first-degree atrioventricular block) was observed on treatment day 3 in 40% and 47% of subjects during administration of saquinavir/ritonavir at a therapeutic dosage of 1000 mg/100 mg twice daily and a supratherapeutic dosage of 1500 mg/100 mg twice daily, respectively, compared to 3% of subjects during administration of the active control (moxifloxacin) and 5% of subjects during administration of placebo. The maximum mean PR interval changes relative to the predose baseline value were 25 msec and 34 msec for the saquinavir/ritonavir therapeutic and supratherapeutic regimens, respectively, while almost no change occurred during the moxifloxacin and placebo arms.
MANAGEMENT: Ritonavir-boosted saquinavir should not be used with other agents that prolong the PR interval.
See also...
Drug Interaction Classification
The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
